我國(guó)從2009年開(kāi)始實(shí)行基本藥物制度，有利于解決用藥貴、用藥難等現(xiàn)實(shí)問(wèn)題。但是基本藥物普及性的提高更加突出了藥物不良反應(yīng)（ADR）監(jiān)測(cè)的重要性，為保障用藥安全，藥品上市后的安全性再評(píng)價(jià)十分重要。為了加強(qiáng)國(guó)家基本藥物ADR的監(jiān)測(cè)工作，闡述我國(guó)基本藥物ADR監(jiān)測(cè)的現(xiàn)狀及存在問(wèn)題，并提出完善法律體系、明晰基本藥物的遴選標(biāo)準(zhǔn)、提高各主體ADR認(rèn)識(shí)的實(shí)施建議，為合理用藥、保障公眾健康提供指導(dǎo)。

In order to obtain drugs conveniently and cheaply, the national essential drug policy has been implemented formed in China since 2009. However, due to the improvement of national essential drug popularity, the adverse drug reaction (ADR) monitoring became more important, and the post-marketing safety re-evaluation is very important for protecting the health of patients. The aim of this article is to guide the rational use of drugs and protect human health, and the current status of ADR monitoring of national essential drugs is discussed. Some advices were provided to enhance the ADR monitoring of national essential drugs, including constituting policy system, detailing the national essential drug criteria, and encouraging the spontaneous reporting of ADRs.